Drug Profile
Research programme: RNA interference-based therapeutics - Generex/Phio Pharmaceuticals
Latest Information Update: 21 Nov 2018
Price :
$50
*
At a glance
- Originator Generex Biotechnology Corporation; RXi Pharmaceuticals Corporation
- Developer Galena Biopharma; Generex Biotechnology Corporation; Phio Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Gene silencing; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies